The estimated Net Worth of Guido J Neels is at least $24.1 million dollars as of 1 September 2024. Mr. Neels owns over 11,904 units of Axogen stock worth over $1,206,036 and over the last 18 years he sold AXGN stock worth over $22,701,000. In addition, he makes $180,000 as Independent Director at Axogen.
Sign up
Mr. Neels AXGN stock SEC Form 4 insiders trading
Guido has made over 12 trades of the Axogen stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 11,904 units of AXGN stock worth $158,085 on 1 September 2024.
The largest trade he's ever made was selling 1,150,000 units of Axogen stock on 20 November 2017 worth over $22,701,000. On average, Guido trades about 38,361 units every 106 days since 2006. As of 1 September 2024 he still owns at least 90,816 units of Axogen stock.
You can see the complete history of Mr. Neels stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Guido Neels biography
Guido J. Neels serves as Independent Director of the Company. Mr. Neels has served as a member of our Board of Directors since August 2015. He has been an operating partner of EW Healthcare Partners L.P. (“EW”) since February 2013. Mr. Neels joined EW as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 until retiring in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation (“Guidant”), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant’s four operating units – Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 to December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 to 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co., Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 to 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors of certain portfolio companies of EW, including Entellus Medical, Endologix and Bioventus. In addition, Mr. Neels also serves on the board of directors for Christel House International and Amici Lovanienses, both not-for-profit organizations, and is an advisor for Novo Holdings in Denmark.
What is the salary of Guido Neels?
As the Independent Director of Axogen, the total compensation of Guido Neels at Axogen is $180,000. There are 10 executives at Axogen getting paid more, with Eric Sandberg having the highest compensation of $1,113,440.
How old is Guido Neels?
Guido Neels is 71, he's been the Independent Director of Axogen since 2016. There are no older and 14 younger executives at Axogen.
What's Guido Neels's mailing address?
Guido's mailing address filed with the SEC is C/O AXOGEN, INC. 13631 PROGRESS BLVD, SUITE 400, ALACHUA, FL, 32615.
Insiders trading at Axogen
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels et Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
What does Axogen do?
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
What does Axogen's logo look like?
Complete history of Mr. Neels stock trades at Axogen, Endologix et Lemaitre Vascular Inc
Axogen executives and stock owners
Axogen executives and other stock owners filed with the SEC include:
-
Eric Sandberg,
Chief Commercial Officer -
Karen Zaderej,
Chairman of the Board, President, Chief Executive Officer -
Gregory Freitag,
Director -
Angelo Scopelianos,
Vice President - Research and Development -
Peter Mariani,
Chief Financial Officer -
Maria Martinez,
Chief Human Resource Officer -
Quentin Blackford,
Independent Director -
Alan Levine,
Independent Director -
Amy Wendell,
Lead Independent Director -
Mark Gold,
Independent Director -
Guido Neels,
Independent Director -
Paul Thomas,
Director -
Brad Ottinger,
Chief Compliance Officer, General Counsel -
Isabelle Billet,
Chief Strategy and Business Development Officer -
Mark Friedman,
Vice President - Regulatory Affairs and Quality Assurance -
Erick DeVinney,
Vice President - Clinical and Translational Sciences -
Mike Donovan,
Vice President - Operations -
James E Deerfield Mgmt L.P....,
-
John P Engels,
Vice President -
Jamie Mark Grooms,
Director -
Robert James Rudelius,
Director -
Joseph M Mandato,
Director -
Shawn F Mccarrey,
SVP of Sales -
Lisa N Colleran,
Director -
Jon S. Gingrich,
Chief Commercial Officer -
Woodlands Fund Ix, L.P. Essex,
10% owner -
Kevin Leach,
Vice President Marketing -
Kathy Johnson Weiler,
Director -
William P. Mr. Burke,
Director -
Lee Robert Jr Johnston,
Chief Financial Officer -
Jill F Schiaparelli,
SVP, Bus. Strategy&Marketing -
John Frederick Harper,
Director -
Bradley Jay Hedger,
Vice President, Sales -
David K Hansen,
VP Finance & Treasurer -
Michael Patrick Donovan,
VP Operations -
Joseph A. Tyndall,
Director -
John Johnson,
Director -
Nir Naor,
CFO -
Marc A Began,
EVP and General Counsel -
Jens Kemp,
Chief Marketing Officer -
Michael D Dale,
CEO and President